Children's Memorial Hospital

Queen's University at Kingston

Cellegy Pharmaceuticals Inc.

Ann & Robert H. Lurie Children's Hospital of Chicago

Lynne-Marie Postovit

Elisabeth Ann Seftor

Mary Jessica Hendrix

Richard Edward Barnet Seftor

Michael A Adams

Jeremy P W Heaton

Charles H Graham

The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity.

Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells

The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

Formulations and methods of using nitric oxide mimetics in cancer treatment

Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.

Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Growing community of inventors

London, Canada

Lynne-Marie Postovit